Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
31 Outubro 2023 - 9:31AM
via InvestorWire —
Lexaria Bioscience Corp. (NASDAQ:
LEXX) today announces its placement in an editorial
published by NetworkNewsWire ("NNW"), one of 60+ brands
within the
Dynamic Brand
Portfolio @
IBN (InvestorBrandNetwork), a
specialized communications platform with a focus on financial news
and content distribution for private and public companies and the
investment community.
To view the full publication, “Can Diabetes, Weight-Loss Drugs
Get Even Better?”,please visit: https://nnw.fm/q9osg
The prestigious “New England Journal of Medicine” recently
published results of a large study of 2,539 adults wherein weight
loss of 49 to 52 pounds was a common outcome. With more than 37
million Americans suffering from diabetes, and with obesity at
epidemic levels, it’s little wonder that millions of people are
singing their praises of the new class of drugs responsible for
these outrageously positive outcomes. GLP-1 agonists are a class of
medications that mainly help manage blood sugar (glucose) levels in
people with type 2 diabetes but are also helping treat obesity.
Seems everyone is excited about controlling blood sugar and easily
losing weight.
But there may be an even better avenue to increased
effectiveness and better outcomes. Lexaria Bioscience Corp.
(NASDAQ: LEXX), a global innovator in drug-delivery platforms,
began diabetes-related formal studies last year with its
DehydraTECH(TM) platform, which showed reduced blood-sugar levels
and lowered body weight. With such encouraging early results,
Lexaria is planning to launch new human and animal studies to
examine whether DehydraTECH processing can make GLP-1 drugs such as
semaglutide even better.
About Lexaria Bioscience Corp.
Lexaria’s patented drug-delivery technology, DehydraTECH(TM),
improves the way active pharmaceutical ingredients (APIs) enter the
bloodstream through oral delivery. Since 2016, DehydraTECH has
repeatedly demonstrated the ability to increase bio-absorption with
cannabinoids, antiviral drugs, PDE5 inhibitors and more.
DehydraTECH has also evidenced an ability to deliver some drugs
more effectively across the blood brain barrier. Lexaria operates a
licensed in-house research laboratory and holds a robust
intellectual property portfolio with 37 patents granted and many
patents pending worldwide.
For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and
updates relating to LEXX are available in the company’s newsroom
at https://ibn.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications
platform with a focus on financial news and content distribution
for private and public companies and the investment community. It
is one of 60+ brands within the Dynamic Brand
Portfolio @ IBN that
delivers: (1) access to a vast network of
wire solutions via InvestorWire to efficiently and
effectively reach a myriad of target markets, demographics and
diverse industries; (2) article
and editorial syndication to 5,000+
outlets; (3) press release
enhancement to ensure maximum
impact; (4) social media
distribution via IBN to millions of social media
followers; and (5) a full array of
tailored corporate communications solutions. With broad reach
and a seasoned team of contributing journalists and writers, NNW is
uniquely positioned to best serve private and public companies that
want to reach a wide audience of investors, influencers, consumers,
journalists and the general public. By cutting through the overload
of information in today’s market, NNW brings its clients
unparalleled recognition and brand awareness. NNW is where breaking
news, insightful content and actionable information converge.
For more information, please
visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or republished:
https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWireNew York, NY www.NetworkNewsWire.com 212.418.1217
Office Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
Lexaria Bioscience (NASDAQ:LEXX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Lexaria Bioscience (NASDAQ:LEXX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024